Stevia Extract Shields Diabetic Muscle From Atrophy by Boosting Mitochondria
New research shows stevia extract reverses insulin resistance signals and protects skeletal muscle from wasting in diabetic cell and mouse models.
Summary
Researchers from Gachon University found that stevia extract (SE) significantly improved skeletal muscle health in type 2 diabetes models. In palmitate-treated C2C12 myotubes, SE reduced lipid buildup and restored anabolic signaling through AKT and mTOR pathways. It also activated key mitochondrial regulators including AMPK, Sirt1, and PGC-1α while suppressing muscle-wasting genes Atrogin-1 and MuRF1. In diabetic db/db mice given oral SE for 35 days, similar protective effects were confirmed in gastrocnemius muscle tissue. These findings position stevia not just as a sweetener substitute but as a bioactive compound with real potential to combat diabetic sarcopenia.
Detailed Summary
Muscle wasting is a serious and underappreciated complication of type 2 diabetes. Chronic insulin resistance, ectopic fat accumulation, and mitochondrial dysfunction progressively erode skeletal muscle mass and function, accelerating sarcopenia and reducing quality of life. Finding safe, natural interventions that target these mechanisms simultaneously is a priority in metabolic and longevity research.
This study examined stevia extract (SE) — derived from the Stevia rebaudiana plant — in two complementary models of diabetic muscle disease. C2C12 myotubes were exposed to palmitic acid to mimic the lipotoxic environment of diabetes, then treated with SE at doses ranging from 12.5 to 100 µg/mL. Separately, genetically diabetic db/db mice received oral SE at 200 or 500 mg/kg per day for 35 days, after which gastrocnemius muscle was analyzed.
In both models, SE produced striking protective effects. Lipid accumulation was significantly reduced, and the anabolic insulin signaling pathway — specifically AKT and mTOR — was restored toward normal. Critically, SE upregulated the AMPK/Sirt1/PGC-1α axis, a master regulatory network governing mitochondrial biogenesis and metabolic flexibility. Downstream effectors PPARα and FGF21 were also elevated, suggesting enhanced fatty acid oxidation capacity. Meanwhile, expression of the muscle atrophy ubiquitin ligases Atrogin-1 and MuRF1 was significantly suppressed in both cell and animal models.
These results indicate SE acts on multiple complementary pathways simultaneously — reducing lipotoxicity, restoring anabolic signals, enhancing mitochondrial quality, and directly suppressing proteolytic atrophy programs. This multi-target profile is particularly valuable since diabetic sarcopenia is itself a multifactorial condition.
Important caveats apply. The animal model (db/db mice) involves severe genetic obesity and diabetes, which may not fully represent human type 2 diabetes. The optimal human dose, bioavailability of active steviol glycosides in muscle tissue, and long-term safety at therapeutic doses remain to be established in clinical trials.
Key Findings
- Stevia extract restored AKT and mTOR anabolic signaling suppressed by palmitate-induced insulin resistance in muscle cells.
- AMPK, Sirt1, PGC-1α, PPARα, and FGF21 were all significantly upregulated, indicating improved mitochondrial biogenesis.
- Muscle atrophy genes Atrogin-1 and MuRF1 were suppressed in both diabetic cell and mouse models.
- Oral SE at 200–500 mg/kg/day for 35 days protected gastrocnemius muscle in db/db diabetic mice.
- Lipid accumulation in skeletal muscle was significantly reduced across multiple SE doses.
Methodology
The study used a two-model design: palmitate-treated C2C12 murine myotubes for in vitro lipotoxicity and db/db mice for in vivo diabetic muscle analysis. SE was administered orally at 200 or 500 mg/kg/day for 35 days in mice, and at 12.5–100 µg/mL in cell culture. Outcome measures included gene expression of atrophy markers, mitochondrial pathway proteins, and lipid content.
Study Limitations
The db/db mouse model involves extreme genetic obesity that may not accurately reflect typical human type 2 diabetes progression. Bioavailability and tissue distribution of stevia's active compounds in human skeletal muscle have not been characterized. The 35-day study duration is insufficient to assess long-term effects on muscle mass or functional outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: